MedDataX Logo

Antimicrobial Stewardship Reduces MDRO Isolates in Critically Ill Patients

NCT ID: NCT02128399

Last Updated: 2014-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

978 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-06-30

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Antimicrobial exposure is known to reduce the selection for various drug-resistant organisms. Numerous studies have demonstrated the association between antimicrobial use and MDR bacteria detection. However, to the investigators knowledge, there is few data to support the concept that reducing antibiotic use actually leads to improvements in antibiotic susceptibilities. Moreover, antimicrobial stewardship was demonstrated to reduce MDRO and was strongly recommended in clinics. As the investigators know, antimicrobial overuse, which occurs commonly in China, induces a severe antibacterial resistance. China's Ministry of Health (MOH) has established a policy about the antimicrobial stewardship. To date, the investigators do not have published documentation the effects of this policy on multidrug-resistant organism (MDRO) in critically ill patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dose Optimization by Pharmacokinetic/Pharmacodynamic of Antibiotics to Improve Clinical Outcome of Carbapenem Resistant Klebsiella Pneumoniae Bloodstream Infections in Critically Ill Patients at Phramongkutklao Hospital

NCT05862402

Carbapenem Resistant Klebsiella Pneumoniae
UNKNOWN PHASE4

Predictors of Rates of Resistant Gram-Negative Bacteria

NCT01075009

Relationship of Carbapenem Use to Carbapenem Resistant Gram-negative Bacteria
COMPLETED

Effect of Direct-from-blood Bacterial Testing on Antibiotic Administration and Clinical Outcomes

NCT06069206

Bloodstream Infection Sepsis Bacterial MRSA Bacteremia +1 more
COMPLETED NA

Quantifying Gram-negative Resistance to Empiric Therapy in the Intensive Care Unit

NCT05171257

Gram-Negative Bacterial Infections
UNKNOWN

Immunosuppression and Intensive Care Unit-acquired Multidrug-resistant Bacteria

NCT06652126

Critically-ill Patients
NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sepsis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

patients before and after intervetion

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients hospitalized in the ICU

Exclusion Criteria

* Patients who were readmitted to the ICU during a single hospital stay
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Jianfeng Xie

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jianfeng Xie

doctor of department of critical care medicine

Responsibility Role SPONSOR_INVESTIGATOR

References

Explore related publications, articles, or registry entries linked to this study.

Ma X, Xie J, Yang Y, Guo F, Gao Z, Shao H, Huang Y, Yang C, Qiu H. Antimicrobial stewardship of Chinese ministry of health reduces multidrug-resistant organism isolates in critically ill patients: a pre-post study from a single center. BMC Infect Dis. 2016 Nov 25;16(1):704. doi: 10.1186/s12879-016-2051-8.

Reference Type DERIVED
PMID: 27887595 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MDRO

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Therapeutic Drug Monitoring in Patients With Difficult-to-Treat Gram-Negative Bacterial Infections
NCT05942157 RECRUITING NA
Different Dosing Strategies of Colistin in Multidrug-Resistant Gram-Negative Bacilli Infections
NCT06843668 RECRUITING PHASE2/PHASE3
Comparison of Solid Organ Transplant
NCT04055922 UNKNOWN
Therapeutic Drug Monitoring of Anti-infectious Drugs in Intensive Care Unit
NCT03339869 UNKNOWN NA
Effect of Antibiotic Choice On ReNal Outcomes (ACORN)
NCT05094154 COMPLETED PHASE4
Seven Versus 14 Days of Antibiotic Therapy for Multidrug-resistant Gram-negative Bacilli Infections
NCT05210387 TERMINATED NA
ICU-acquired Colonization and Infection Related to MDR in Immunocompromised Patients
NCT04043793 COMPLETED
Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia
NCT05210439 RECRUITING PHASE4
Personalized Optimization of Antibiotic Therapy in Pulmonary Sepsis Critically Ill Patients Through Application of Rapid Microbiological Diagnostic Technologies and Pharmacokinetic/Pharmacodynamic Modelling
NCT06956053 NOT_YET_RECRUITING NA
PREdiction of CEphalosporinase Producing Enterobacteria During Ventilator-associated Pneumonia for Therapeutic Stewardship
NCT05486130 UNKNOWN
Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
NCT03309657 COMPLETED PHASE1/PHASE2
Pharmacokinetics of Antibiotics in Critically Ill Patients Receiving CVVHF
NCT04800952 UNKNOWN NA
Randomized-controlled Trial (RCT) on Combination Antibiotic for Infections Caused by Gram-negative Bacteria
NCT02134106 WITHDRAWN PHASE2/PHASE3
Bacteremia Antibiotic Length Actually Needed for Clinical Effectiveness
NCT03005145 COMPLETED NA
Efficacy of Cotrimoxazole as a De-escalation Treatment of Ventilator-Associated Pneumonia in Intensive Care Unit
NCT05696093 RECRUITING PHASE3
Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU
NCT05511129 UNKNOWN
Risk Factors for Multidrug Resistant Bacteria at ICU Admission
NCT05983861 UNKNOWN
Rapid Detection of Bacterial Resistance by MALDI-TOF MS and Antibiotic Savings
NCT02860247 COMPLETED
Antibiotic Treatment Duration (7 vs 14 Days) Comparison in Blood Stream Infection Causes by Enterobacteriaceae
NCT02400268 COMPLETED PHASE3
Real-world Daptomycin Use in Chinese ICUs
NCT03588637 COMPLETED
Concentration Monitoring of Anti-infective Drugs in Human Cerebrospinal Fluid and Its Clinical Application
NCT06729619 ACTIVE_NOT_RECRUITING
Clinical Outcomes With Ceftolozane-tazobactam for MDR Pseudomonas Infections
NCT03510351 UNKNOWN
Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU
NCT02846298 UNKNOWN
Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China
NCT03245632 UNKNOWN
Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin
NCT02443064 UNKNOWN PHASE4